SC Pharmaceuticals(SZ:002693) Zheng Quan Shi Bao Wang·2025-10-13 09:20Core Viewpoint - *ST Shuangcheng has received marketing approval from the Australian Therapeutic Goods Administration (TGA) for injectable bortezomib, indicating a significant advancement in its product portfolio and potential market opportunities in treating multiple myeloma and mantle cell lymphoma patients [1] Summary by Categories Product Approval - The company has obtained a marketing license for injectable bortezomib from the TGA [1] - The approved indications include treatment for previously untreated multiple myeloma patients who are unsuitable for high-dose chemotherapy, as well as those who have received at least one prior treatment and have disease progression [1] Treatment Combinations - Bortezomib is approved for use in combination with melphalan and prednisone for treating previously untreated multiple myeloma patients [1] - It is also indicated for use in conjunction with high-dose chemotherapy and autologous stem cell rescue for patients under 65 years old who have not received prior treatment [1] - Additionally, it is approved for use with rituximab, cyclophosphamide, doxorubicin, and prednisone for treating adult patients with previously untreated mantle cell lymphoma [1]